Biora Therapeutics Announces Sale of Cell-Free DNA Patent Rights
SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech…
News
Assertio Holdings, Inc. Signs Exclusive License for Sympazan® (clobazam) Oral Film from Aquestive Therapeutics, Inc.
Trailing 12 Month Revenues of Sympazan Were $9.5 MillionAssertio Paid $9.0 Million Upfront, Additional $6.0…
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
ENCINITAS, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) — Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a…
Aphaia Pharma Announces Enrollment of First Patient in Phase 2 Study of APH-012 for Chronic Weight Management in Individuals with Obesity
ZUG, Switzerland, Oct. 27, 2022 (GLOBE NEWSWIRE) — Aphaia Pharma, a clinical-stage biopharmaceutical company harnessing…
Software Effective Solutions Subsidiary MEDCANA (OTC: SFJW) Announces Successful Launch of Test Greenhouses for Microclimates and Genetics with Colombia Partner Firms
MedCana’s initial focus is on partnering and developing companies in Latin America with an initial…
Salarius Pharmaceuticals Presents Favorable Preclinical Data on SP-3164 at the 5th Annual Targeted Protein Degradation Conference
Data showcased novel compound with potential for improved anti-cancer activity over other molecular glues Salarius…
CRISPR Therapeutics Announces Planned Transition of Chief Operating Officer
ZUG, Switzerland and BOSTON, Oct. 27, 2022 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a…
BioAtla to Announce Third Quarter 2022 Financial Results and Provide Business Highlights on November 3, 2022
SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) — BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage…
Rain Therapeutics to Report Third Quarter 2022 Financial Results and Highlights of Recent Progress on November 10, 2022
NEWARK, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) — Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a…
Selecta Biosciences to Host Conference Call and Webcast to Discuss Third Quarter 2022 Financial Results and Provide Business Update
WATERTOWN, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology…
Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202
WILMETTE, Ill., Oct. 27, 2022 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical…
Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom’s Macroglobulinemia
MB-106 demonstrated 100% overall response rate in Waldenstrom macroglobulinemia Data to be presented by Fred…
Jounce Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 10, 2022
CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) — Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage…
Mindset Pharma Announces Poster Presentations at Two Upcoming Scientific Conferences
5th Annual Neuropsychiatric & Psychedelics Drug Development Summit in Boston, MA on October 31st Neuroscience…
Biomea Fusion Announces First Patient Dosed with Chronic Lymphocytic Leukemia (CLL) in COVALENT-101 Trial
COVALENT-101 now includes patients with relapsed/refractory (R/R) CLL BMF-219 is the first menin inhibitor in…
PDS Biotech Provides Highlights from Head and Neck Cancer KOL Roundtable
Jared Weiss, MD, Lead Investigator for the VERSATILE-002 clinical trial combining PDS0101 and KEYTRUDA®, presents…
Burning Rock Announces Publication of Prospectus in connection with Direct Listing on the London Stock Exchange
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR PART, DIRECTLY OR INDIRECTLY, IN OR…
Ocugen to Host Conference Call on Tuesday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2022 Financial Results
MALVERN, Pa., Oct. 27, 2022 (GLOBE NEWSWIRE) — Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ:…
Syneos Health Adds HUB Patient Suite to Deployment Solutions Business
Brings Together the Industry’s Most Comprehensive Suite of Modular Patient Services, Optimizing Patient Experience from…
HUTCHMED Initiates a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) —…